TORONTO, Canada, May 2, 2019 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, will be presenting a poster at the American Urological Association 2019 meeting (in collaboration with University of Western Ontario and Lawson Health Research Institute).

TORONTO, Canada, April 24, 2019 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1st, 10:30am at the Metro Toronto Convention Centre.

TORONTO, Canada, April 24, 2019 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, will be presenting at The Association for Research in Vision and Ophthalmology 2019 meeting.

Interface Biologics Inc (IBI) is a company from Toronto, Ontario, Canada that develops innovative materials for both Medtech and Pharmaceutical applications.

Closely-held Interface Biologics, best known for improving the safety and efficacy of medical devices through its Endexo surface modification technology, is pegging its future growth on biotech, with an initial focus on unmet needs in ophthalmology.

Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the addition of Kelley Dealhoy, to the IBI management team, as Vice President of Business Development.

Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce a positive pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its novel dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases.

U of T professor Paul Santerre (Dentistry, IBBME) has been named the Baxter Chair of Health Technology and Commercialization. Created through a $2.5-million investment from the Baxter Corporation to the University Health Network (UHN), the chair will enable Santerre to drive commercialization and entrepreneurship initiatives at both UHN and U of T.

Paul Santerre recently flew to Boston to help launch a cerebral catheter that incorporates an anti-clotting polymer additive created by Interface Biologics, the company he co-founded nearly two decades ago based on his University of Toronto lab work.

Interface Biologics Inc. ("IBI"), a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI's Endexo® technology.

Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation, has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo™

AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the publication of a nurse-led, peripherally inserted central catheter (PICC) study in the July 4, 2017 edition of CMAJ Open, an online medical and health research journal of the Canadian Medical Association.

Peripherally inserted central catheters (PICCs) provide enormous benefit to patients. However, recent publications have highlighted relatively high PICC-associated complication rates. We report on patient and device outcomes from a nurse-led program.

The molecules he works with are so small they can’t be seen with the naked eye, but for Professor Paul Santerre, who is being honoured with the 2017 Governor General’s Innovation Award, it’s what you do with those molecules that counts. One of six awardees to be recognized at a special ceremony at Rideau Hall on May 23, Santerre’s award recognizes his sweeping entrepreneurial vision for scientific inquiry — and its vital role in shaping Canada’s innovation economy.

TORONTO, Canada, September 13, 2016 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of transformative biomedical-polymer technologies that improve the safety and effectiveness of medical devices, is pleased to announce the

August 25, 2007 - Toronto, Canada Interface Biologics Inc., Toronto, Ontario is very pleased to announce the addition of Dr. Nicolas Chronos, M. D. to its Advisory Board.

AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration has granted 510(k) clearance f

Interface Biologics a part of Life Sciences Ontario (LSO) promotional video showcasing the many strengths and assets that Ontario's diverse life sciences sector has to offer.

Toronto, ON, Canada, September 6, 2012 – Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that AngioDynamics has been granted 510(k) clearance by the U.S. Foo

September 17, 2012 – What began in the Dentistry lab of Professor Paul Santerre more than a decade ago is now Interface Biologics Inc. (IBI) - a privately-held company poised to transform the market for medical devices in the United States.

October 2, 2012 – Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Sandra Beach Lin to the Board of Directors. Ms. Beach Lin is an experien

February 27, 2013 - Professor Paul Santerre began his career at the University in 1993 in the Faculty of Dentistry and is a member of the Centre for Biomaterials, where he has conducted research into biomaterials - molecules and polymers designed to inter

Toronto, ON, Canada, March 5, 2013 - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Dr. Paul Santerre, PhD, Chief Scientific Officer at IBI, was presen

ALBANY, N.Y., Aug. 20, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the U.S. Food and Drug Admi

ALBANY, N.Y., June 12, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that its BioFlo peripherally inser

Interface Biologics, Inc, the spin-off company begun by Professor Paul Santerre, has received its second FDA clearance in less than a year for AngioDynamic’s BioFlo Port catheter. The catheter is made with Endexo technology, a biomaterial substance invent

ALBANY, N.Y., Sept. 23, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, and Interface Biologics Inc. (IBI),

TORONTO, ONTARIO--(Marketwired - Jan. 14, 2014) - Interface Biologics Inc. (IBI), and Q3 Medical Devices Limited are pleased to announce the signing of a joint development and commercialization agreement to combine IBI's Kinesyx bioactive oligomers with t

Toronto, ON, Canada, May 12, 2014 -- Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Dion Madsen to the Board of Directors. Mr. Madsen is

Toronto, ON, Canada, July 7, 2014 -- EY is pleased to announce this year’s gravity-defying Entrepreneur Of The Year finalists in Ontario. “This year’s finalists prove that the future of entrepreneurship in our country is brighter than ever,” says Colleen

Toronto, ON, Canada, October 6, 2014 -- Often singled out for his academic leadership and research, U of T Professor Paul Santerre is being celebrated for a different reason this month. His leadership in moving his biomaterials discovery, Surface Modifyin

Toronto, ON, Canada, October 6, 2014 -- Each year for the past 33 years, the Ernest C. Manning Awards Foundation has recognized Canadians who have developed and successfully marketed their breakthrough ideas. This year’s four winners, unveiled exclusively

TORONTO, May 8, 2007 - Interface Biologics Inc., Toronto , Ontario , is very pleased to announce the addition of Dr. Robert Schwartz, M.D. to its Advisory Board.

Tom Reeves leads the team of scientists and engineers at Interface Biologics - a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. See pg

AngioDynamics a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the launch of the BioFlo Midline catheter indicated for short-term intravenous thera

Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of medical devices, is pleased to announce the completion of a Series B financing round led by DSM Venturing and existing

For the past 5 years, I have lived with a peripherally inserted central catheter (PICC) for treatment of a chronic urinary tract infection(UTI) associated with a neurogenic bladder. As a child, I experienced several kidney infections before being diagnose

TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (Frankfurt Stock Exchange: FME and NYSE: FMS)

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1 million investment by the Investment Accelerator Fund-Life Sciences (IAF-LS).

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce a definitive license and supply agreement with Navilyst Medical, a leading manufacturer of image-guided medic

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (NYSE: FMS), the worlds' largest integrated provider of dialysis products and ser

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the addition of Mr. Kevin Palmer to the IBI management team as Vice President of Finance.

Toronto, Canada, February 14th, 2011 – For Immediate Release Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Arthur L. Rosenthal to Cha

At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B financing led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.

Toronto, Canada, January 10th, 2011 – For Immediate Release Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the completion of a $7M series B financing, le

Toronto, Canada, January 4, 2011 - For Immediate Release Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the signing of a joint development agreement with

Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, today announced that it received ISO 13485:2003 certification.

Dentistry professor Paul Santerre understands the world of start-up companies. Ten years ago, well before assuming his current role as director of the Institute of Biomaterials and Biomedical Engineering, Santerre discovered a way to control the adverse r

Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, is pleased to announce the signing of an evaluation and exclusive license option agreement with Fresenius Medical C

Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the safety and effectiveness of medical devices, is proud to announce that one of it's co-founders...

As CEO of Interface Biologics, Tom Reeves doesn’t dwell on what might have been. For example, a few years ago, as COO of OccuLogix, he came within the blink of an eye of a billion-dollar breakthrough to treat dry age-related macular degeneration.

Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today the appointment of Dr. John Denstedt, Dr. Curtis Nickel and Dr. Leonard Pinchuk to its Scientific Advisory Boar

Just about everyone on the planet will get a sliver of something in a finger at one time or another. Whether it is wood, metal, plastic or glass, if you don’t get it out, it soon becomes a painful mess of infection. Your body is just not meant to have for

À peu près tout le monde sur la planète recevra, un jour ou l’autre, un éclat de quelque chose dans le doigt. Qu’il soit de bois, de métal, de plastique ou de verre, si vous ne le retirez pas, votre doigt ne tardera pas à vous faire mal et à s’infecter. V

Implants often rely on antimicrobial coatings to prevent infections. But the release of antibacterial agents via diffusion from a biomaterial’s surface may not be the most effective approach for combating biofilm formation on implants. With this in mind,

Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today that experienced medical device executive, Arthur L. Rosenthal Ph.D., has been appointed to its Board of Direct

Toronto - December 9, 2008 - FOR IMMEDIATE RELEASE - Interface Biologics secures $5mm round of financing Interface Biologics Inc. - a privately held developer of novel biomedical-polymers for use in implantable medical devices - is announcing that it h

Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings. In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin coated cathete